echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Front oncol: Professor Huilai Zhang's team retrospectively analyzed the clinical features and outcomes of 926 cases of follicular lymphoma

    Front oncol: Professor Huilai Zhang's team retrospectively analyzed the clinical features and outcomes of 926 cases of follicular lymphoma

    • Last Update: 2022-10-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Follicular lymphoma (FL) is an indolent lymphoma in most patients who are sensitive to chemotherapy or immunochemotherapy (IC), and although overall survival in patients during the rituximab era improves, FL is considered an incurable disease


    FL is a more aggressive histological transformation (tFL), usually to diffuse large B-cell lymphoma (DLBCL), which is an important clinical event associated with adverse outcomes with an annual risk of histological transformation (HT) of 2% to 3%


    Scholars in Western countries have described in detail the demographics, baseline disease characteristics, initial treatment strategies, and outcomes of FL patients, while data on FL patients in China are limited, especially in the absence of single-center large-sample studies


    Results of the study

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.